This report segments the neuropathy pain treatment market by indication (diabetic neuropathy, chemotherapy-induced neuropathy pain, postherpetic neuralgia, and others) and geography (North America, Europe, APAC, South America, and Middle East and Africa)
NEW YORK, Oct. 4, 2022 /PRNewswire/ -- One of the key trends in the neuropathy pain treatment market growth is the growing focus on emerging economies. Research institutes and vendors are focusing on tapping potential treatments in emerging economies, which will bring substantial growth opportunities. The increasing number of individuals requiring pain treatment has increased the demand for neuropathy pain treatment in countries such as China, India, and Brazil. Research institutes have also issued guidelines to address unmet needs in the treatment of pain. For instance, in APAC, a group of pain specialists has created tailored guidelines for each region. In addition, vendors are establishing new units in emerging economies such as Brazil to expand their presence in the market. Such initiatives will drive market growth during the forecast period.
The global neuropathy pain treatment market size is expected to grow by USD 3.81 billion between 2021 to 2026. In addition, the growth momentum of the market will accelerate at a CAGR of 9.18%, according to Technavio's latest market report.
Get a comprehensive report summary that describes the market size and forecast along with research methodology. The FREE sample report is available in PDF format
Neuropathy Pain Treatment Market: Market Segmentation
By indication, the diabetic neuropathy segment will be the largest contributor to market growth during the forecast period. Most of the currently approved therapies provide only symptomatic relief. Hence, there is a need for disease-modifying treatments that might slow, prevent, or reverse the progression of nerve damage. Vendors are extensively focusing on R&D activities to address this unmet medical need. For instance, in January 2019, Daiichi Sankyo Company received marketing approval in Japan for the Tarlige drug for the treatment of peripheral neuropathic pain.
In terms of geography, North America will present significant opportunities for market vendors due to the factors such as the growing prevalence of diabetes. The region will account for 33% of the market's growth during the forecast period. Moreover, market growth in this region will be faster than the growth of the market in other regions. The US and Canada are the key countries for the neuropathy pain treatment market in North America.
Neuropathy Pain Treatment Market: Major Growth Drivers
The focus on the development of novel therapeutics for postherpetic neuralgia is driving the neuropathy pain treatment market growth. Postherpetic neuralgia is a complication of shingles caused by the chickenpox virus. There are various drugs for the treatment of postherpetic neuralgia. However, the lack of effective therapeutics has negatively impacted the adoption rates. Therefore, vendors are focusing on the development of potential alternatives. Currently, there are around nine molecules for the treatment of postherpetic neuralgia in different stages of development. Such developments will fuel the growth of the global neuropathy pain treatment market growth during the forecast period.
Technavio has identified key trends, drivers, and challenges in the market, which will help vendors improve their strategies to stay ahead of their competitors. View our FREE PDF Sample Report
Neuropathy Pain Treatment Market: Key Vendors
Abbott Laboratories, Assertio Therapeutics Inc., Astellas Pharma Inc., AstraZeneca Plc, Aurobindo Pharma Ltd., Baxter International Inc., Biogen Inc., Bristol Myers Squibb Co., Dr. Reddys Laboratories Ltd, Eli Lilly, and Co., Endo International Plc, GlaxoSmithKline Plc, Johnson and Johnson, Mallinckrodt Plc, Novartis AG, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd, VistaGen Therapeutics Inc., among others, are the main players in the market.
Neuropathy Pain Treatment Market: Reasons to Buy Our Report
- CAGR of the market during 2022-2026
- Detailed information on factors that will help the neuropathy pain treatment market grow during the next five years
- Approximation of the neuropathy pain treatment market size and its contribution to the parent market
- Forecasts on upcoming trends and changes in consumer behavior
- The growth of the neuropathy pain treatment market across North America, Europe, APAC, South America, and Middle East and Africa
- Analysis of the market's competitive landscape and detailed information on vendors
- Comprehensive details of factors that will challenge the growth of neuropathy pain treatment market vendors
Related Reports
Consumer Healthcare Market by Product and Geography - Forecast and Analysis 2022-2026: The consumer healthcare market share is expected to increase by USD 123.78 billion from 2021 to 2026.
Periodontal Dental Services Market by End-user, Service, and Geography - Forecast and Analysis 2022-2026: The periodontal dental services market share is expected to increase by USD 10.61 billion from 2021 to 2026.
Neuropathy Pain Treatment Market Scope |
|
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 9.18% |
Market growth 2022-2026 |
USD 3.81 billion |
Market structure |
Fragmented |
YoY growth (%) |
11.03 |
Regional analysis |
North America, Europe, APAC, South America, and Middle East and Africa |
Performing market contribution |
North America at 33% |
Key consumer countries |
US, Canada, India, Germany, and UK |
Competitive landscape |
Leading companies, competitive strategies, consumer engagement scope |
Companies profiled |
Abbott Laboratories, Assertio Therapeutics Inc., Astellas Pharma Inc., AstraZeneca Plc, Aurobindo Pharma Ltd., Baxter International Inc., Biogen Inc., Bristol Myers Squibb Co., Dr Reddys Laboratories Ltd, Eli Lilly and Co., Endo International Plc, GlaxoSmithKline Plc, Johnson and Johnson, Mallinckrodt Plc, Novartis AG, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd, and VistaGen Therapeutics Inc. |
Market Dynamics |
Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, and market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Browse Health Care Market Reports
Table of Contents
1 Executive Summary
- 1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Indication
- Exhibit 06: Executive Summary – Chart on Incremental Growth
- Exhibit 07: Executive Summary – Data Table on Incremental Growth
- Exhibit 08: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 09: Parent market
- Exhibit 10: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 11: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 12: Market segments
- 3.3 Market size 2021
- 3.4 Market outlook: Forecast for 2021-2026
- Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
- Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
- Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
- Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
4 Five Forces Analysis
- 4.1 Five forces summary
- Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
- 4.2 Bargaining power of buyers
- Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026
- 4.3 Bargaining power of suppliers
- Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
- 4.4 Threat of new entrants
- Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
- 4.5 Threat of substitutes
- Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
- 4.6 Threat of rivalry
- Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
- 4.7 Market condition
- Exhibit 23: Chart on Market condition - Five forces 2021 and 2026
5 Market Segmentation by Indication
- 5.1 Market segments
- Exhibit 24: Chart on Indication - Market share 2021-2026 (%)
- Exhibit 25: Data Table on Indication - Market share 2021-2026 (%)
- 5.2 Comparison by Indication
- Exhibit 26: Chart on Comparison by Indication
- Exhibit 27: Data Table on Comparison by Indication
- 5.3 Diabetic neuropathy - Market size and forecast 2021-2026
- Exhibit 28: Chart on Diabetic neuropathy - Market size and forecast 2021-2026 ($ million)
- Exhibit 29: Data Table on Diabetic neuropathy - Market size and forecast 2021-2026 ($ million)
- Exhibit 30: Chart on Diabetic neuropathy - Year-over-year growth 2021-2026 (%)
- Exhibit 31: Data Table on Diabetic neuropathy - Year-over-year growth 2021-2026 (%)
- 5.4 Chemotherapy-induced neuropathy pain - Market size and forecast 2021-2026
- Exhibit 32: Chart on Chemotherapy-induced neuropathy pain - Market size and forecast 2021-2026 ($ million)
- Exhibit 33: Data Table on Chemotherapy-induced neuropathy pain - Market size and forecast 2021-2026 ($ million)
- Exhibit 34: Chart on Chemotherapy-induced neuropathy pain - Year-over-year growth 2021-2026 (%)
- Exhibit 35: Data Table on Chemotherapy-induced neuropathy pain - Year-over-year growth 2021-2026 (%)
- 5.5 Postherpetic neuralgia - Market size and forecast 2021-2026
- Exhibit 36: Chart on Postherpetic neuralgia - Market size and forecast 2021-2026 ($ million)
- Exhibit 37: Data Table on Postherpetic neuralgia - Market size and forecast 2021-2026 ($ million)
- Exhibit 38: Chart on Postherpetic neuralgia - Year-over-year growth 2021-2026 (%)
- Exhibit 39: Data Table on Postherpetic neuralgia - Year-over-year growth 2021-2026 (%)
- 5.6 Others - Market size and forecast 2021-2026
- Exhibit 40: Chart on Others - Market size and forecast 2021-2026 ($ million)
- Exhibit 41: Data Table on Others - Market size and forecast 2021-2026 ($ million)
- Exhibit 42: Chart on Others - Year-over-year growth 2021-2026 (%)
- Exhibit 43: Data Table on Others - Year-over-year growth 2021-2026 (%)
- 5.7 Market opportunity by Indication
- Exhibit 44: Market opportunity by Indication ($ million)
6 Customer Landscape
- 6.1 Customer landscape overview
- Exhibit 45: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
7 Geographic Landscape
- 7.1 Geographic segmentation
- Exhibit 46: Chart on Market share by geography 2021-2026 (%)
- Exhibit 47: Data Table on Market share by geography 2021-2026 (%)
- 7.2 Geographic comparison
- Exhibit 48: Chart on Geographic comparison
- Exhibit 49: Data Table on Geographic comparison
- 7.3 North America - Market size and forecast 2021-2026
- Exhibit 50: Chart on North America - Market size and forecast 2021-2026 ($ million)
- Exhibit 51: Data Table on North America - Market size and forecast 2021-2026 ($ million)
- Exhibit 52: Chart on North America - Year-over-year growth 2021-2026 (%)
- Exhibit 53: Data Table on North America - Year-over-year growth 2021-2026 (%)
- 7.4 Europe - Market size and forecast 2021-2026
- Exhibit 54: Chart on Europe - Market size and forecast 2021-2026 ($ million)
- Exhibit 55: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
- Exhibit 56: Chart on Europe - Year-over-year growth 2021-2026 (%)
- Exhibit 57: Data Table on Europe - Year-over-year growth 2021-2026 (%)
- 7.5 APAC - Market size and forecast 2021-2026
- Exhibit 58: Chart on APAC - Market size and forecast 2021-2026 ($ million)
- Exhibit 59: Data Table on APAC - Market size and forecast 2021-2026 ($ million)
- Exhibit 60: Chart on APAC - Year-over-year growth 2021-2026 (%)
- Exhibit 61: Data Table on APAC - Year-over-year growth 2021-2026 (%)
- 7.6 South America - Market size and forecast 2021-2026
- Exhibit 62: Chart on South America - Market size and forecast 2021-2026 ($ million)
- Exhibit 63: Data Table on South America - Market size and forecast 2021-2026 ($ million)
- Exhibit 64: Chart on South America - Year-over-year growth 2021-2026 (%)
- Exhibit 65: Data Table on South America - Year-over-year growth 2021-2026 (%)
- 7.7 Middle East and Africa - Market size and forecast 2021-2026
- Exhibit 66: Chart on Middle East and Africa - Market size and forecast 2021-2026 ($ million)
- Exhibit 67: Data Table on Middle East and Africa - Market size and forecast 2021-2026 ($ million)
- Exhibit 68: Chart on Middle East and Africa - Year-over-year growth 2021-2026 (%)
- Exhibit 69: Data Table on Middle East and Africa - Year-over-year growth 2021-2026 (%)
- 7.8 US - Market size and forecast 2021-2026
- Exhibit 70: Chart on US - Market size and forecast 2021-2026 ($ million)
- Exhibit 71: Data Table on US - Market size and forecast 2021-2026 ($ million)
- Exhibit 72: Chart on US - Year-over-year growth 2021-2026 (%)
- Exhibit 73: Data Table on US - Year-over-year growth 2021-2026 (%)
- 7.9 Germany - Market size and forecast 2021-2026
- Exhibit 74: Chart on Germany - Market size and forecast 2021-2026 ($ million)
- Exhibit 75: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
- Exhibit 76: Chart on Germany - Year-over-year growth 2021-2026 (%)
- Exhibit 77: Data Table on Germany - Year-over-year growth 2021-2026 (%)
- 7.10 UK - Market size and forecast 2021-2026
- Exhibit 78: Chart on UK - Market size and forecast 2021-2026 ($ million)
- Exhibit 79: Data Table on UK - Market size and forecast 2021-2026 ($ million)
- Exhibit 80: Chart on UK - Year-over-year growth 2021-2026 (%)
- Exhibit 81: Data Table on UK - Year-over-year growth 2021-2026 (%)
- 7.11 Canada - Market size and forecast 2021-2026
- Exhibit 82: Chart on Canada - Market size and forecast 2021-2026 ($ million)
- Exhibit 83: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
- Exhibit 84: Chart on Canada - Year-over-year growth 2021-2026 (%)
- Exhibit 85: Data Table on Canada - Year-over-year growth 2021-2026 (%)
- 7.12 India - Market size and forecast 2021-2026
- Exhibit 86: Chart on India - Market size and forecast 2021-2026 ($ million)
- Exhibit 87: Data Table on India - Market size and forecast 2021-2026 ($ million)
- Exhibit 88: Chart on India - Year-over-year growth 2021-2026 (%)
- Exhibit 89: Data Table on India - Year-over-year growth 2021-2026 (%)
- 7.13 Market opportunity by geography
- Exhibit 90: Market opportunity by geography ($ million)
8 Drivers, Challenges, and Trends
- 8.1 Market drivers
- 8.2 Market challenges
- 8.3 Impact of drivers and challenges
- Exhibit 91: Impact of drivers and challenges in 2021 and 2026
- 8.4 Market trends
9 Vendor Landscape
- 9.1 Overview
- 9.2 Vendor landscape
- Exhibit 92: Overview on Criticality of inputs and Factors of differentiation
- 9.3 Landscape disruption
- Exhibit 93: Overview on factors of disruption
- 9.4 Industry risks
- Exhibit 94: Impact of key risks on business
10 Vendor Analysis
- 10.1 Vendors covered
- Exhibit 95: Vendors covered
- 10.2 Market positioning of vendors
- Exhibit 96: Matrix on vendor position and classification
- 10.3 Abbott Laboratories
- Exhibit 97: Abbott Laboratories - Overview
- Exhibit 98: Abbott Laboratories - Business segments
- Exhibit 99: Abbott Laboratories - Key news
- Exhibit 100: Abbott Laboratories - Key offerings
- Exhibit 101: Abbott Laboratories - Segment focus
- 10.4 Assertio Therapeutics Inc.
- Exhibit 102: Assertio Therapeutics Inc. - Overview
- Exhibit 103: Assertio Therapeutics Inc. - Business segments
- Exhibit 104: Assertio Therapeutics Inc. - Key offerings
- Exhibit 105: Assertio Therapeutics Inc. - Segment focus
- 10.5 AstraZeneca Plc
- Exhibit 106: AstraZeneca Plc - Overview
- Exhibit 107: AstraZeneca Plc - Product / Service
- Exhibit 108: AstraZeneca Plc - Key news
- Exhibit 109: AstraZeneca Plc - Key offerings
- 10.6 Baxter International Inc.
- Exhibit 110: Baxter International Inc. - Overview
- Exhibit 111: Baxter International Inc. - Business segments
- Exhibit 112: Baxter International Inc. - Key news
- Exhibit 113: Baxter International Inc. - Key offerings
- Exhibit 114: Baxter International Inc. - Segment focus
- 10.7 Dr Reddys Laboratories Ltd
- Exhibit 115: Dr Reddys Laboratories Ltd - Overview
- Exhibit 116: Dr Reddys Laboratories Ltd - Business segments
- Exhibit 117: Dr Reddys Laboratories Ltd - Key offerings
- Exhibit 118: Dr Reddys Laboratories Ltd - Segment focus
- 10.8 Eli Lilly and Co.
- Exhibit 119: Eli Lilly and Co. - Overview
- Exhibit 120: Eli Lilly and Co. - Product / Service
- Exhibit 121: Eli Lilly and Co. - Key offerings
- 10.9 Endo International Plc
- Exhibit 122: Endo International Plc - Overview
- Exhibit 123: Endo International Plc - Business segments
- Exhibit 124: Endo International Plc - Key news
- Exhibit 125: Endo International Plc - Key offerings
- Exhibit 126: Endo International Plc - Segment focus
- 10.10 Johnson and Johnson
- Exhibit 127: Johnson and Johnson - Overview
- Exhibit 128: Johnson and Johnson - Business segments
- Exhibit 129: Johnson and Johnson - Key news
- Exhibit 130: Johnson and Johnson - Key offerings
- Exhibit 131: Johnson and Johnson - Segment focus
- 10.11 Pfizer Inc.
- Exhibit 132: Pfizer Inc. - Overview
- Exhibit 133: Pfizer Inc. - Product / Service
- Exhibit 134: Pfizer Inc. - Key news
- Exhibit 135: Pfizer Inc. - Key offerings
- 10.12 Sanofi SA
- Exhibit 136: Sanofi SA - Overview
- Exhibit 137: Sanofi SA - Business segments
- Exhibit 138: Sanofi SA - Key news
- Exhibit 139: Sanofi SA - Key offerings
- Exhibit 140: Sanofi SA - Segment focus
11 Appendix
- 11.1 Scope of the report
- 11.2 Inclusions and exclusions checklist
- Exhibit 141: Inclusions checklist
- Exhibit 142: Exclusions checklist
- 11.3 Currency conversion rates for US$
- Exhibit 143: Currency conversion rates for US$
- 11.4 Research methodology
- Exhibit 144: Research methodology
- Exhibit 145: Validation techniques employed for market sizing
- Exhibit 146: Information sources
- 11.5 List of abbreviations
- Exhibit 147: List of abbreviations
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article